Warner Sallman

Groundbreaking USW Guide on 'Stop Work Authority' Will Protect Workers

Retrieved on: 
Wednesday, July 20, 2022
Rubber industry in Malaysia, Warner Sallman, List of environmental ministries, Public sector, Injury, Workplace (Health, Safety and Welfare) Regulations 1992, SWA, Michaels, Dan Sullivan (U.S. senator), National Labor Relations Act of 1935, Fatality, United Steelworkers, Explosion, Metal, OSHA, Occupational safety and health, Glass, Chemical safety, Paper, Multimedia, Assistant, Firestone Tire and Rubber Company, Barack Obama, Newborn Screening Saves Lives Act of 2007, Mining, Labour, USW, George Washington University School of Engineering and Applied Science, Death, Senate, Safety data sheet, Public health, Health insurance, Management, Online shopping, Safety, Health

PITTSBURGH, July 20, 2022 /PRNewswire/ -- The United Steelworkers (USW) today announced the publication of a new groundbreaking guide from its Health, Safety, and Environment Department.

Key Points: 
  • PITTSBURGH, July 20, 2022 /PRNewswire/ -- The United Steelworkers (USW) today announced the publication of a new groundbreaking guide from its Health, Safety, and Environment Department.
  • "The United Steelworkers is proud to issue this path-breaking guide," said USW International President Tom Conway.
  • "In addition, workers often face challenges, including retaliation, in their efforts to stop unhealthy or unsafe work."
  • Debra Coyle, executive director of the New Jersey Work Environment Council, the nation's longest-standing state labor-environmental alliance, said that the guide can help protect workers and communities.

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CBL, Twitter, Lymphatic system, Chemokine, Clinical trial, COVID-19, Inflammation, Health, Rheumatoid arthritis, Padrón, Blood, Incidence, Granulocyte-macrophage colony-stimulating factor, Warner Sallman, Judgement, National Health, RAS, Leukemia, Chronic myelomonocytic leukemia, Survival, Risk, GM-CSF, SAHMRI, Goal, III, Hypersensitivity, SEC, Medical Research Council, Government, Precision medicine, Medical Research Future Fund, Medicare, CEO, Nasdaq, Acute leukemia, Patient, Mutation, South Australian Health and Medical Research Institute, University, LinkedIn, Geography, Cancer, Hematology, Knowledge, NRAS, TET2, National Health and Medical Research Council, Azacitidine, Forward-looking statement, GM, Associate, KRAS, Progression-free survival, Pharmaceutical industry, Vaccine, Risk management, PREACH-M, Humanigen, Inc., SAHMRI, PREACH-M, HUMANIGEN, INC., SAHMRI

The PREACH-M trial is designed to focus on Chronic Myelomonocytic Leukemia (CMML) patients who carry mutations believed to drive the leukemia.

Key Points: 
  • The PREACH-M trial is designed to focus on Chronic Myelomonocytic Leukemia (CMML) patients who carry mutations believed to drive the leukemia.
  • Patients with RAS pathway mutations such as KRAS, NRAS, or CBL, will be enrolled in the lenzilumab and azacitidine arm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • A phase 1 study of lenzilumab, a humaneered recombinant anti-human granulocyte-macrophage colony- stimulating factor (anti-hGM-CSF) antibody, for chronic myelomonocytic leukemia (CMML).